Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics

Gene Therapy Applications

“…Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer 483 (Gordon and Hall, 2010;Hall et al, 2010); (iii) it is no longer appropriate to deny the mathematical potentiality of a targeted genetic medicine, in light of the quantitative demonstrations of single agent dose-dependent anti-tumor activity, along with the recent advances in biopharmaceutical vector production that have raised the potency of the clinical-grade vectors more than two orders of magnitude (Gordon and Hall, 2009). Indeed, as the development and validation of the world's first (Waehler et al, 2007;Gordon and Hall, 2010), but no longer only (see Reximmune-C; Gordon et al, , 2008, tumortargeted genetic medicine is recognized, the promise and potential of the platform have begun to percolate into the general medical literature, impacting the practice of clinical oncology (Hughes, 2009), medical imaging (Bjojani et al, 2010), medicinal nanotechnology (Peach et al, 2009), and gene therapy (Sverdlov, 2009), as well as the discussions of bedside bioethics (Toh, 2011) and the practical applications of tumor immunology (Zolnik et al, 2010).…”

Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer

“…Indeed, as the development and validation of the world's first (Waehler et al, 2007;Gordon and Hall, 2010), but no longer only (see Reximmune-C; Gordon et al, , 2008, tumortargeted genetic medicine is recognized, the promise and potential of the platform have begun to percolate into the general medical literature, impacting the practice of clinical oncology (Hughes, 2009), medical imaging (Bjojani et al, 2010), medicinal nanotechnology (Peach et al, 2009), and gene therapy (Sverdlov, 2009), as well as the discussions of bedside bioethics (Toh, 2011) and the practical applications of tumor immunology (Zolnik et al, 2010). Looking forward into the future, it is only a matter of time (see Gordon and Hall, 2009) when the progression of metastatic disease is no longer considered to be intractable, and the poor prognosis of chemotherapy-resistant cancer is summarily improved.…”

Gene Therapy Applications

“…The triad of forbidding challenges of undeveloped biotechnology, institutional incredulity, and scientific skepticism have been confronted and allayed by a significant amount of scientific and clinical data that heralded the advent of pathotropic targeting as an enabling biotechnological platform with a series of sound conclusions: (i) it is no longer impossible to reach the fabric of the nature of malignant disease itself (i.e., collagen patefacio, from Gordon and Hall, 2009); (ii) it is no longer impossible to deliver a sufficient number of therapeutic genes to the appropriate site and get them to stay there long enough to impact and reverse the course of metastatic disease (Gordon and Hall, 2010;Hall et al, 2010); (iii) it is no longer appropriate to deny the mathematical potentiality of a targeted genetic medicine, in light of the quantitative demonstrations of single agent dose-dependent anti-tumor activity, along with the recent advances in biopharmaceutical vector production that have raised the potency of the clinical-grade vectors more than two orders of magnitude (Gordon and Hall, 2009). Indeed, as the development and validation of the world's first (Waehler et al, 2007;Gordon and Hall, 2010), but no longer only (see Reximmune-C; Gordon et al, , 2008, tumortargeted genetic medicine is recognized, the promise and potential of the platform have begun to percolate into the general medical literature, impacting the practice of clinical oncology (Hughes, 2009), medical imaging (Bjojani et al, 2010), medicinal nanotechnology (Peach et al, 2009), and gene therapy (Sverdlov, 2009), as well as the discussions of bedside bioethics (Toh, 2011) and the practical applications of tumor immunology (Zolnik et al, 2010).…”